Source-grounded facts extracted from OSR Holdings, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
OSR Holdings, Inc. entered into Asset Purchase Agreement with Vaximm AG valued at $30,000,000 (effective 2026-05-27).
“On May 27, 2026, OSR Holdings, Inc. (the “Company”) entered into an Asset Purchase Agreement (the “Asset Purchase Agreement”) with Vaximm AG (“Vaximm”), a clinical-stage biopharmaceutical company organized under the laws of Switzerland.”
OSR Holdings, Inc. entered into License Agreement with BCM Europe AG valued at up to $815,000,000 (effective 2026-04-29).
“Global Exclusive License Agreement On April 29, 2026, OSR Holdings, Inc. (the “Company”), together with its wholly-owned subsidiary Vaximm AG (“Vaximm”), entered into a Global Exclusive License Agreement (the “License”
OSR Holdings, Inc. incurred convertible notes of $1,055,555.55 with White Lion Capital, LLC at 5% per annum maturing nine-month anniversary of its issuance date.
“On April 7, 2026, the Company issued the Note in the original principal amount of $1,055,555.55, bearing interest at 5% per annum and maturing in nine months.”
OSR Holdings, Inc. entered into Note Purchase Agreement with White Lion Capital, LLC valued at principal amount of $1,055,555.55 Senior Secured Convertible Promissory Note; Company received $500, (effective 2026-04-07).
“Also on April 7, 2026, the Company entered into a Note Purchase Agreement (the “Note Purchase Agreement”) with White Lion, pursuant to which the Company agreed to issue a Senior Secured Convertible Promissory Note in the principal amount of $1,055,555.55 (the “Note”).”
OSR Holdings, Inc. entered into Amendment No. 2 to the Common Stock Purchase Agreement with White Lion Capital, LLC valued at introduces additional purchase mechanisms including intraday purchase notices and fixed purchase not (effective 2026-04-07).
“On April 7, 2026, OSR Holdings, Inc. (the “Company”) entered into Amendment No. 2 to the Common Stock Purchase Agreement (the “ELOC Amendment”) with White Lion Capital, LLC, d/b/a White Lion GBM Innovation Fund (“White Lion”), which amends that certain Common Stock Purchase Agreement, dated February 25, 2025, as previously amended.”
OSR Holdings, Inc. entered into Binding Term Sheet with BCM Europe AG valued at up to $815.0 million in milestone payments (effective 2026-03-27).
“On March 27, 2026, OSR Holdings, Inc. (the “Company” or “OSRH”), together with its wholly-owned subsidiary Vaximm AG (“Vaximm”), entered into a Binding Term Sheet (the “Term Sheet”) with BCM Europe AG (“BCME”) relating to a revised global exclusive license arrangement for VXM01.”
OSR Holdings, Inc. received a nasdaq extension granted notice regarding minimum bid price (rules 5550(a)(2)).
“March 5, 2026, OSR Holdings, Inc. (the “Company”) received a written notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that Nasdaq has granted the Company an additional 180 calendar day period, or until August 31, 2026, to regain compliance with Nasdaq Listing Rule 5550(a)(2), which requires listed securities to maintain a minimum bid price of $1.00 per share. As previously disclosed, on September 5, 2025, the Company received notice from Nasdaq that the closing bid price of the Company’s common stock had fallen below the required”
OSR Holdings, Inc. completed an acquisition involving Woori IO Co., Ltd. (closed 2026-01-26).
“On January 26, 2026 (the “Closing Date”), OSR Holdings Co., Ltd. (“OSRK”), a subsidiary of OSR Holdings, Inc. (the “Company”), completed the share exchange transaction contemplated by the Share Exchange Agreement dated October 13, 2025”
OSR Holdings, Inc. entered into Binding Term Sheet with BCM Europe AG valued at $30.0 million (comprised of $15.0 million in cash and $15.0 million in digital assets) and up to $81 (effective 2025-01-13).
“On January 13, 2025, Vaximm AG, a wholly-owned subsidiary of OSR Holdings, Inc. (the “Company”), entered into a Binding Term Sheet (the “Term Sheet”) with BCM Europe AG (“BCME”), the largest shareholder of the Company, relating to a proposed global exclusive license of Vaximm’s VXM01 oral cancer immunotherapy platform.”
OSR Holdings, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).
“September 5, 2025, OSR Holdings, Inc. (the “Company”) received a written notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company is not in compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2), because the closing bid price of the Company’s common stock has been below $1.00 per share for 30 consecutive business days. The notice has no immediate effect on the listing or trading of the Company’s securities, which will continue to trade on The Nasdaq Capital Market under the symbols “OSRH” and”
Dr. Constance Höfer was appointed as Chief Scientific Officer at OSR Holdings, Inc..
“On March 24, 2025, the Board of Directors of OSR Holdings, Inc. (the “Company”) appointed Dr. Constance Höfer as the Company’s Chief Scientific Officer , effective immediately.”
Sang Hoon Kim was appointed as Head of Corporate Venture Capital at OSR Holdings, Inc..
“Sang Hoon Kim is Head of Corporate Venture Capital”
Gihyoun Bang was appointed as Chief Financial Officer at OSR Holdings, Inc..
“Gihyoun Bang is Chief Financial Officer”
Jun Chul Whang was appointed as Chief Legal Officer and Secretary at OSR Holdings, Inc..
“Jun Chul Whang is Chief Legal Officer and Secretary”
Kuk Hyoun Hwang was appointed as President and Chief Executive Officer at OSR Holdings, Inc..
“Kuk Hyoun Hwang is the President and Chief Executive Officer of the Company”
David J. Yoo resigned as Chief Financial Officer at OSR Holdings, Inc..
“David J. Yoo resigned from his position as BLAC's Chief Financial Officer.”
Sang Hyun Kim was appointed as Director at OSR Holdings, Inc..
“On June 23, 2024, the Board of Directors (the “Board”) of Bellevue Life Sciences Acquisition Corp. (the “Company”) appointed Mr. Sang Hyun Kim as a director, effective immediately.”
Radclyffe Roberts resigned as Member of the Board of Directors at OSR Holdings, Inc..
“On June 7, 2024, Radclyffe Roberts also provided notice of his resignation as member of the Board and as a member of the Board’s Compensation Committee (the “Compensation Committee”) as well as a member and chair of the Board’s M&A Committee.”
Inchul Chung resigned as Member of the Board of Directors at OSR Holdings, Inc..
“On June 7, 2024, Inchul Chung provided notice of his resignation as a member of the Board of Directors (the “Board”) of Bellevue Life Sciences Acquisition Corp. (the “Company”) and as a member of the Board’s Audit Committee (the “Audit Committee”).”
Phil Geon Lee was appointed as Director at OSR Holdings, Inc..
“On May 27, 2024, the BLAC Board appointed Mr. Phil Geon Lee as a director, effective immediately.”
Steven Reed resigned as Director at OSR Holdings, Inc..
“On May 24, 2024, Steven Reed provided notice of his resignation as a member of the BLAC Board of Directors (the “ BLAC Board ”) effective immediately”
OSR Holdings, Inc.: The Company amended its charter to extend the business combination deadline from May 14, 2024 to November 14, 2024 (effective 2024-05-14).
“On May 14, 2024, the Company held a special meeting of its stockholders (the “ Special Meeting ”). At the Special Meeting, the Company’s stockholders approved a proposal (the “ Extension Amendment Proposal ”) to amend to the Company’s Amended and Restated Certificate of Incorporation (the “ Charter ”) to allow the Company to extend the date by which the Company must consummate a business combination from May 14, 2024, to November 14, 2024. The Certificate of Amendment to the Charter (the “ Charter Amendment ”) was filed with the Delaware Secretary of State and has an effective date of May 14, 2024.”
OSR Holdings, Inc. shareholders approved approval of adjournment of the Special Meeting to a later date or dates, if necessary, to permit further solicitation and vote of proxies in the event that there are insufficient votes to approve the Extension Amendment Proposal or to establish quorum at the 2024-05-14 meeting.
“Proposal 2 - Adjournment Proposal The stockholders approved the proposal to approve the adjournment of the Special Meeting to a later date or dates, if necessary, to permit further solicitation and vote of proxies in the event that there are insufficient votes to approve the Extension Amendment Proposal or to establish quorum by the votes set forth in the table below: FOR AGAINST ABSTAIN BROKER NON-VOTES 3,831,081 507,414 — —”
OSR Holdings, Inc. shareholders approved amendment to the Charter to allow the Company to extend the date by which the Company must consummate a business combination from May 14, 2024 to November 14, 2024 at the 2024-05-14 meeting.
“Proposal 1 - Extension Amendment Proposal The stockholders approved the proposal to amend the Charter to allow the Company to extend the date by which the Company must consummate a business combination from May 14, 2024 to November 14, 2024 by the votes set forth in the table below: FOR AGAINST ABSTAIN BROKER NON-VOTES 3,835,399 503,096 — —”
OSR Holdings, Inc. incurred loan of $140,000 with Bellevue Global Life Sciences Investors LLC at not interest bearing maturing the earlier of: (i) December 31, 2024 or (ii) the date on which the Company consummates an initial business combination.
“On May 14, 2024, Bellevue Life Sciences Acquisition Corp. (the " Company ") issued an unsecured promissory note (the " Promissory Note ") in the principal amount of $140,000 to Bellevue Global Life Sciences Investors LLC (" BGLSI "), the sponsor of the Company.”
OSR Holdings, Inc. incurred loan of $50,000 with Bellevue Global Life Sciences Investors LLC at not interest bearing maturing December 31, 2024 or the date on which the Company consummates an initial business combination.
“On April 17, 2024, Bellevue Life Sciences Acquisition Corp. (the “ Company ”) issued an unsecured promissory note (the “ Promissory Note ”) in the principal amount of $50,000 to Bellevue Global Life Sciences Investors LLC (“ BGLSI ”), the sponsor of the Company.”
OSR Holdings, Inc. received a nasdaq extension granted notice regarding shareholders (rules 5550(a)(3)).
“April 17, 2024, the Company received a written notice from Nasdaq indicating that the staff of Nasdaq (the “ Staff ”) has determined, based on its review of the Company’s compliance plan, to grant the Company an extension of time to regain compliance with the Minimum Public Holders Requirement. The terms of the extension are as follows: on or before August 13, 2024, the Company must file with Nasdaq documentation from its transfer agent, or independent source, that demonstrates that its common stock has a minimum of 300 public holders. In the event the Company does not satisfy the terms, the S”
OSR Holdings, Inc. incurred loan of $1,200,000 with Bellevue Global Life Sciences Investors, LLC at not interest bearing maturing earlier of: (i) December 31, 2024 or (ii) the date on which the Company consummates an initial business combination.
“On April 8, 2024, Bellevue Life Sciences Acquisition Corp. (the “ Company ”) issued an unsecured promissory note (the “ Promissory Note ”) in the principal amount of $1,200,000 to Bellevue Global Life Sciences Investors, LLC (“ BGLSI ”), the sponsor of the Company. The Promissory Note is not interest bearing and is payable in full on the earlier of: (i) December 31, 2024 or (ii) the date on which the Company consummates an initial business combination (the “ Maturity Date ” ) .”
OSR Holdings, Inc. incurred loan of $60,000 with Josh Pan at not interest bearing maturing earlier of: (i) August 8, 2024 or (ii) the date on which the Company consummates an initial business combination.
“On March 8, 2024, Bellevue Life Sciences Acquisition Corp. (the “ Company ”) issued an unsecured promissory note (the “ Promissory Note ”) in the principal amount of $60,000 to Josh Pan”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.